333 related articles for article (PubMed ID: 16531229)
41. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
42. Proteasome inhibitors in pediatric cancer treatment.
Bachmann AS
Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
[TBL] [Abstract][Full Text] [Related]
43. The therapeutic potential of the proteasome in leukaemia.
McCloskey SM; McMullin MF; Walker B; Irvine AE
Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
[TBL] [Abstract][Full Text] [Related]
44. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.
Clerc J; Florea BI; Kraus M; Groll M; Huber R; Bachmann AS; Dudler R; Driessen C; Overkleeft HS; Kaiser M
Chembiochem; 2009 Nov; 10(16):2638-43. PubMed ID: 19746508
[TBL] [Abstract][Full Text] [Related]
45. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
[TBL] [Abstract][Full Text] [Related]
46. Proteasome inhibitors: poisons and remedies.
Meiners S; Ludwig A; Stangl V; Stangl K
Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
[TBL] [Abstract][Full Text] [Related]
47. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
48. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
49. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.
Groll M; Huber R
Methods Enzymol; 2005; 398():329-36. PubMed ID: 16275340
[TBL] [Abstract][Full Text] [Related]
50. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
51. Affinity labeling of the proteasome by a belactosin A derived inhibitor.
Hasegawa M; Kinoshita K; Nishimura C; Matsumura U; Shionyu M; Ikeda S; Mizukami T
Bioorg Med Chem Lett; 2008 Oct; 18(20):5668-71. PubMed ID: 18801655
[TBL] [Abstract][Full Text] [Related]
52. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
[TBL] [Abstract][Full Text] [Related]
53. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
54. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
55. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Kiziltepe T; Bilgicer B
J Med Chem; 2014 Jun; 57(12):5282-92. PubMed ID: 24897555
[TBL] [Abstract][Full Text] [Related]
56. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.
Tan X; Osmulski PA; Gaczynska M
Curr Med Chem; 2006; 13(2):155-65. PubMed ID: 16472211
[TBL] [Abstract][Full Text] [Related]
57. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
59. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
60. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Milo LJ; Lai JH; Wu W; Liu Y; Maw H; Li Y; Jin Z; Shu Y; Poplawski SE; Wu Y; Sanford DG; Sudmeier JL; Bachovchin WW
J Med Chem; 2011 Jul; 54(13):4365-77. PubMed ID: 21634429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
